BeOne Medicines AG (ONC) Stock Price & Analysis
BeOne Medicines AG (ONC) closed at USD 374.08 on Thursday, October 15, 2026, up 6.43% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 351.48; the Oct 15, 2026 session ranged USD 356.61–375.64 on volume of 720,559 shares. Market capitalization is $42.56B, with a 52-week range of USD 253.95–385.22 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ONC.md
Key facts (ONC)
- Analysts: Buy (mean 1.78 on a 1–5 scale) (27 analysts), mean target USD 435.72 (range 370–528).
- Total return with dividends: 1Y +17.6% vs S&P 500 +18.1%; 5Y +4.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD 1.88, revenue estimate $1.76B.
Analysts (ONC)
Consensus Buy (mean 1.78 on a 1–5 scale), 27 analysts; mean target USD 435.72 (low 370, high 528).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | RBC Capital | Target raised | Outperform | $450 → $459 |
| 2026-10-07 | Truist Securities | Target raised | Buy | $418 → $420 |
| 2026-10-01 | JP Morgan | Target raised | Overweight | $425 → $445 |
| 2026-09-10 | Barclays | Target raised | Overweight | $407 → $415 |
| 2026-08-06 | TD Cowen | Target raised | Buy | $424 → $454 |
| 2026-08-06 | RBC Capital | Target lowered | Outperform | $451 → $450 |
| 2026-08-06 | Truist Securities | Target raised | Buy | $416 → $418 |
| 2026-08-06 | Guggenheim | Target raised | Buy | $420 → $430 |
| 2026-08-06 | Barclays | Target raised | Overweight | $403 → $407 |
| 2026-08-06 | Citizens | Target raised | Market Outperform | $396 → $405 |
| 2026-07-23 | JP Morgan | Target raised | Overweight | $415 → $425 |
| 2026-07-14 | Barclays | Target lowered | Overweight | $409 → $403 |
Total return (dividends reinvested) (ONC)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +17.6% | +4.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +17.7% | +0.9% |
| Volatility (annualized) | 35.0% | 50.0% |
| Max drawdown | -31.1% (Nov 2025→Jun 2026) | -65.8% (Oct 2021→Apr 2024) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 374.08 |
|---|---|
| Change | ▲ 6.43% (up) |
| Previous Close | USD 351.48 |
| Open | USD 357 |
| Day Range | USD 356.61 – 375.64 |
| 52-Week Range | USD 253.95 – 385.22 |
| Volume | 720,559 shares |
| Market Cap | $42.56B |
| Exchange | NMS |
Technical Analysis (ONC)
Nexqual's technical model rates ONC "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.36 (neutral) |
| vs SMA50 | Above (USD 359.43) |
| MACD | 0.69 (positive) |
Analyst Ratings (ONC)
Wall Street analysts rate ONC "Buy" based on 27 analysts, with a mean price target of USD 435.72 (range USD 370–528), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 435.72 |
| High Target | USD 528 |
| Low Target | USD 370 |
| Buy / Hold / Sell | 26 / 1 / 0 |
Earnings (ONC)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 1.88 |
| Revenue Estimate | $1.76B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.05 vs est 1.63 ▲ beat |
| 2026-03-31 | USD 1.96 vs est 0.81 ▲ beat |
| 2025-12-31 | USD 0.58 vs est 1.3 ▼ miss |
| 2025-09-30 | USD 1.09 vs est 0.86 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (ONC)
| Total Revenue | $6.13B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +29.60% |
| Gross Margin | +88.89% |
| Operating Margin | +19.06% |
| Profit Margin | +10.70% |
| ROE | +14.66% |
| Debt / Equity | 0.4 |
| Current Ratio | 3.41 |
| Total Cash | $5.10B |
| Total Debt | $2.05B |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $941.74M (17.6% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (ONC)
Nexqual rates BeOne Medicines AG's overall financial health "Strong" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +40% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 89%, operating 19% |
| Balance Sheet | Strong — $5.10B cash vs $2.05B debt, net cash position |
| Cash Flow | Strong — FCF $942M (FY ended Dec 2025, 10-K), 18% margin |
| Efficiency | Mixed — ROE 15%, ROA 7.5% |
Ownership (ONC)
| Insider Ownership | +17.28% |
|---|---|
| Institutional Ownership | +33.28% |
| Shares Outstanding | 104.92M |
| Float | 80.96M |
| Short % of Float | +2.39% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (ONC)
BeOne Medicines AG is led by John V. Oyler (age 57), Co-Founder, Executive Chairman & CEO, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Co-Founder, Executive Chairman & CEO | John V. Oyler (age 57) |
|---|---|
| President and Global Head of Research & Development | Wang Lai (age 48) |
| Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Xiaodong Wang (age 62) |
| Chief Financial Officer | Aaron Rosenberg (age 48) |
| Chief Technology Officer | Marcello Damiani (age 55) |
Major Backers & Investors (ONC)
Notable institutional backers of BeOne Medicines AG include Baker Bros. Advisors, LP, Primecap Management Company, Capital International Investors, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 8.02% |
| Primecap Management Company | 4.56% |
| Capital International Investors | 3.83% |
| NEW PERSPECTIVE FUND | 2.43% |
| FMR, LLC | 2.26% |
| Capital Group | 2.05% |
| Citadel | 1.3% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 1.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.22% |
| BlackRock | 1.17% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | USD 189.26 | ▲ 0.44% |
| RPRX | Royalty Pharma plc | USD 59.62 | ▲ 5.39% |
| ARGX | argenx SE | USD 846.27 | ▲ 5.44% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 234.03 | ▲ 4.56% |
| ROIV | Roivant Sciences Ltd. | USD 34.04 | ▲ 2.07% |
| GMAB | Genmab A/S | USD 37.82 | ▲ 3.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt